SCHEMBL500072

SCHEMBL500072

O=C(O)c1cc(Cl)ccc1Br

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.63
ALDH1A1 P00352 1/20 0.63
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
TSHR P16473 2/20 0.57
CASP1 P29466 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HSD17B10 Q99714 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GRIK1 P39086 2/20 0.49
MYC P01106 2/20 0.49
GAA P10253 1/20 0.49
NR4A1 P22736 1/20 0.49
ANO1 Q5XXA6 1/20 0.48
F7 P08709 1/20 0.47
F3 P13726 1/20 0.47
AKR1C4 P17516 1/20 0.45
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
AKR1C1 Q04828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3480768 0.98 TP53 (0.61) TP53ALDH1A1CA1CA2TSHR
SCHEMBL3480767 0.96 TP53 (0.59) TP53ALDH1A1CA1CA2TSHR
SCHEMBL15137264 0.83 ALDH1A1 (0.48) TP53ALDH1A1CA1CA2TSHR
SCHEMBL1669829 0.83 ALDH1A1 (0.47) TP53ALDH1A1CA1CA2TSHR
SCHEMBL395189 0.83 SMN1; SMN2 (0.63) TP53ALDH1A1CA1CA2TSHR
SCHEMBL24821886 0.81 ALDH1A1 (0.55) TP53ALDH1A1CA1CA2TSHR
SCHEMBL29494150 0.81 F2R (0.48) TP53ALDH1A1CA1CA2TSHR
SCHEMBL3121226 0.81 F2R (0.48) TP53ALDH1A1CA1CA2TSHR
SCHEMBL1000440 0.79 ALDH1A1 (0.71) TP53ALDH1A1CA1CA2TSHR
SCHEMBL19514758 0.79 ALDH1A1 (0.71) TP53ALDH1A1CA1CA2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634196-A1 PERACID PROMOTERS IN THE IRIDIUM-CATALYZED HYDROSILYLATION SYNTHESIS OF HALOALKYLORGANOSILANES Momentive Performance Materials GmbH (DE) 2025-10-22 EP claimed
CN-118790960-B Hollow nano tubular carbon nitride structure modification and photocatalytic decomposition hydrogen production method 中国电建集团西北勘测设计研究院有限公司 2025-01-14 CN claimed
CN-118790960-A Hollow nano tubular carbon nitride structure modification and photocatalytic decomposition hydrogen production method 中国电建集团西北勘测设计研究院有限公司 2024-10-18 CN claimed
WO-2024126692-A1 PERACID PROMOTERS IN THE IRIDIUM-CATALYZED HYDROSILYLATION SYNTHESIS OF HALOALKYLORGANOSILANES MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) 2024-06-20 WO claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-102351790-B Method for synthesizing 7-bromo-6-chloro-4-quinazolinone UNIV NANCHANG 2013-12-04 CN claimed
CN-102351790-A Method for synthesizing 7-bromo-6-chloro-4-quinazolinone UNIV NANCHANG 2012-02-15 CN claimed
CN-1651428-A Preparation method of hydrobromic acid antifebrile dichroanone SHANGHAI YINNUO BIOCHEMICAL SC (CN) 2005-08-10 CN claimed
CN-122036551-A Cypress alkyl ketone hydroxyoxaester derivative, preparation method and application thereof 贵州省天然产物研究中心 2026-05-15 CN disclosed
US-20260116868-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-04-30 US disclosed
US-12605369-B2 Amido-substituted heterocyclic compounds and methods of use thereof for the treatment of herpes viruses MERCK SHARP & DOHME LLC (US) 2026-04-21 US disclosed
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 US disclosed
US-20260041672-A1 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof UNIV EMORY (US) 2026-02-12 US disclosed
US-12465595-B2 Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions, and uses thereof EMORY UNIVERSITY (US) 2025-11-11 US disclosed
US-5130318-A Hypotensive agents and for treatment of congestive heart failure IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-07-14 US disclosed
CN-1055925-A Pyridine derivate and preparation method thereof ICI PLC (GB) 1991-11-06 CN disclosed
EP-0453210-A2 Pyridine derivatives ZENECA LIMITED (GB) 1991-10-23 EP disclosed
EP-0023569-B1 DERIVATIVES OF CARBOXYLIC ACIDS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM Dr. Karl Thomae GmbH (DE) 1983-06-22 EP disclosed
EP-0023569-A1 Derivatives of carboxylic acids, their preparation and medicaments containing them Dr. Karl Thomae GmbH (DE) 1981-02-11 EP disclosed
US-3987186-A ANTIALLERGENS BOEHRINGER INGELHEIM GMBH (DT) 1976-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041672-A1 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof CFTR, SCNN1B, CLCN2 TP53 3750/4885ALDH1A1 2972/4885CA1 4673/4885
US-20260116868-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBLC, CBL TP53 1943/4885ALDH1A1 3286/4885CA1 4437/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 TP53 4662/4885ALDH1A1 1507/4885CA1 3778/4885
US-12465595-B2 Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions, and uses thereof CFTR, CLCN2, SLC26A4 TP53 2736/4885ALDH1A1 3631/4885CA1 4864/4885
US-12605369-B2 Amido-substituted heterocyclic compounds and methods of use thereof for the treatment of herpes viruses CXCR1, CCR1, CLIC1 TP53 2817/4885ALDH1A1 2477/4885CA1 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.